MedTrace Logo

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

NCT06751524 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-05-15

No results posted yet for this study

Summary

This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Conditions

Interventions

DRUG

Botensilimab

Administered via an intravenous (IV) infusion of Botensilimab + Balstilimab combination (BOT+BAL).

DRUG

Balstililmab

Administered via an IV infusion of Botensilimab + Balstilimab combination (BOT+BAL).

Sponsors & Collaborators

  • Agenus Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Agenus Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06751524 on ClinicalTrials.gov